TEZSPIRE by AstraZeneca and Amgen shows significant benefits in reducing nasal polyp severity

From Nasdaq.: 2025-03-01 20:30:40

AstraZeneca and Amgen’s TEZSPIRE showed significant benefits in reducing nasal polyp severity, surgeries, and corticosteroid use in patients with chronic rhinosinusitis with nasal polyps compared to placebo. The Phase III trial results demonstrated a decrease in Nasal Polyp Score by -2.065 and nasal congestion by -1.028 at week 52 with early improvements seen as early as week two. TEZSPIRE also reduced the need for nasal polyp surgery by 98% and systemic corticosteroid treatment by 88%. The treatment was well tolerated with no significant safety differences from the placebo group. Regulatory filings for TEZSPIRE in CRSwNP are under review in multiple regions.



Read more at Nasdaq.: AZN: TEZSPIRE Reduces Nasal Polyp Severity And Surgery Need In CRSwNP Patients In Phase III Trial